GDC-0134 ( DrugBank: GDC-0134 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2

2. 筋萎縮性側索硬化症

---

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03237741 (ClinicalTrials.gov)	August 7, 2017	31/7/2017	Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants	A Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing Potential	Amyotrophic Lateral Sclerosis	Drug: Reference capsule GDC-0134;Drug: Prototype capsule GDC-0134;Drug: rabeprazole	Genentech, Inc.	Quotient Clinical	Completed	30 Years	65 Years	Female	24	Phase 1	United Kingdom
2	NCT02655614 (ClinicalTrials.gov)	May 31, 2016	7/1/2016	A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis	A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: GDC-0134;Drug: Placebo;Drug: Rabeprazole;Drug: Midazolam;Drug: Caffeine	Genentech, Inc.	NULL	Completed	18 Years	N/A	All	54	Phase 1	United States;Canada;Netherlands